Innovations in Rejection Surveillance after Heart Transplantation

Innovations in Rejection Surveillance after Heart Transplantation

MonteHeart Lectures via YouTube Direct link

The Molecular Landscape of Rejection: Using rejection associated transcripts as classifiers

21 of 37

21 of 37

The Molecular Landscape of Rejection: Using rejection associated transcripts as classifiers

Class Central Classrooms beta

YouTube videos curated by Class Central.

Classroom Contents

Innovations in Rejection Surveillance after Heart Transplantation

Automatically move to the next video in the Classroom when playback concludes

  1. 1 Intro
  2. 2 Relevant Financial Relationship Disclosure Statement
  3. 3 Number of Adult and Pediatric Heart Transplants by Year and Location
  4. 4 Adult Heart Transplants Diagnosis
  5. 5 Adult Heart TransplantsKaplan-Meier Survival by Era
  6. 6 Innovations in Rejection Surveillance after Heart Transplantation
  7. 7 Invasive Monitoring Attenuation through Gene Expression (IMAGE) Trial
  8. 8 Combined Primary Endpoint
  9. 9 DNA the Molecule of Life
  10. 10 Cell-Free DNA (cfDNA) is Found in Circulating Blood
  11. 11 Cell-Free DNA to Detect Heart Allograft Acute Rejection Study
  12. 12 Longitudinal %ddcfDNA measures after transplant
  13. 13 biopsy graded rejection
  14. 14 Allograft dysfunction by echocardiography
  15. 15 What are the clinical implications?
  16. 16 Endomyocardial Biopsy (EMB)
  17. 17 Intrinsic Problems of the Current Pathology Approach to Diagnosis of Rejection
  18. 18 Common Histological Artefacts that Mimic Rejection
  19. 19 Intragraft mRNA Assessment of Rejection
  20. 20 How Molecular Analysis Works
  21. 21 The Molecular Landscape of Rejection: Using rejection associated transcripts as classifiers
  22. 22 Archetype Analysis
  23. 23 Comparing the A1,2,3 Archetypes for kidney, heart, and lung as estimated by expression of rejection-associated transcripts (RATs)
  24. 24 The INTERHEART Study
  25. 25 Updated rejection and Injury archetype diagnoses
  26. 26 Examples of Heart Transplant Endomyocardial Biopsy with updated MMDx-Heart Reports
  27. 27 Reconcile discrepancies: Injury Repair Response Associated Transcripts
  28. 28 MMDx Results according to ISHLT pathology grading (AMR)
  29. 29 ¡Box system potential for risk stratification
  30. 30 Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy: Study design
  31. 31 Latent class mixed modelling
  32. 32 Baseline characteristics
  33. 33 Identification of 4 trajectories of CAV
  34. 34 Validation of the 4 trajectories in Europe and in the US
  35. 35 Determinants of trajectories: multivariable analysis
  36. 36 On-line calculator
  37. 37 Summary

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.